文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

《2022年全球癌症统计报告》:数据来源、方法及全球癌症负担概述

The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide.

作者信息

Filho Adalberto M, Laversanne Mathieu, Ferlay Jacques, Colombet Murielle, Piñeros Marion, Znaor Ariana, Parkin Donald M, Soerjomataram Isabelle, Bray Freddie

机构信息

Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.

The African Cancer Registry Network, Oxford, UK.

出版信息

Int J Cancer. 2025 Apr 1;156(7):1336-1346. doi: 10.1002/ijc.35278. Epub 2024 Dec 17.


DOI:10.1002/ijc.35278
PMID:39688499
Abstract

The data sources and methods used to develop global cancer incidence and mortality statistics-the GLOBOCAN estimates-for the year 2022 are documented in this article, alongside a brief overview of the global cancer burden. The estimates, made available in 185 countries or territories worldwide for 36 cancer sites by sex and age, are based on the best available local data sources, namely population-based cancer registries (for incidence) and national vital statistics (for mortality). In males, lung cancer was the most commonly diagnosed cancer worldwide in 2022 (1.57 million new cases [95% UI: 1.56-1.58]), followed by prostate cancer (1.47 million [1.46-1.48]). With 2.30 million (2.28-2.30) new cases estimated in 2022, breast cancer was the most diagnosed cancer in females, followed by lung cancer (0.91 million [0.90-0.91 million]) and cervical cancer (0.66 million [0.66-0.67]). The most common causes of cancer death in males and females were lung cancer (1.23 million [1.22-1.24]) and breast cancer (0.67 million [0.66-0.67]), respectively.

摘要

本文记录了用于编制2022年全球癌症发病率和死亡率统计数据(即全球癌症负担估计数)的数据源和方法,同时简要概述了全球癌症负担。这些估计数涵盖全球185个国家或地区的36种癌症部位,按性别和年龄分类,基于现有的最佳本地数据源,即基于人群的癌症登记处(用于发病率)和国家生命统计数据(用于死亡率)。在男性中,肺癌是2022年全球最常诊断出的癌症(157万例新病例[95%不确定区间:156 - 158万例]),其次是前列腺癌(147万例[146 - 148万例])。2022年估计有230万例(228 - 230万例)新病例,乳腺癌是女性中最常诊断出的癌症,其次是肺癌(91万例[90 - 91万例])和宫颈癌(66万例[66 - 67万例])。男性和女性癌症死亡的最常见原因分别是肺癌(123万例[122 - 124万例])和乳腺癌(67万例[66 - 67万例])。

相似文献

[1]
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide.

Int J Cancer. 2025-4-1

[2]
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018-9-12

[3]
Cancer statistics for the year 2020: An overview.

Int J Cancer. 2021-4-5

[4]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[5]
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Int J Cancer. 2014-10-9

[6]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

[7]
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Int J Cancer. 2018-12-6

[8]
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

Lancet. 2024-5-18

[9]
The Global Burden of Cancer 2013.

JAMA Oncol. 2015-7

[10]
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.

Lancet. 2024-5-18

引用本文的文献

[1]
[New insights from basic research on testicular germ cell tumors and updated tumorigenesis].

Urologie. 2025-9-8

[2]
An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.

Cancer Med. 2025-9

[3]
Global patterns and trends in cancer-related premature death and their impact on life expectancy across 185 countries: a population-based analysis.

Mil Med Res. 2025-9-3

[4]
Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma.

Clin Exp Med. 2025-9-1

[5]
Knowledge, attitudes and practices regarding cervical cancer screening among women in the Dindaeng community, Bangkok, Thailand: a cross-sectional community-based study.

BMJ Open. 2025-8-31

[6]
LOC100506691 Is an Oncogenic Long Noncoding RNA that Promotes Growth and Motility of Lung Cancer Cells.

Cancer Genomics Proteomics. 2025

[7]
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.

Hepatol Commun. 2025-8-29

[8]
Mechanism of RCD and the Role of Different Death Signaling Pathways in Cancer.

Biomedicines. 2025-8-2

[9]
The Significance of CEA and CA 19-9 Levels in Serum and Peritoneal Fluid in Colorectal Cancer Patients in the Context of Peritoneal Metastases and Cytology Results.

Cancers (Basel). 2025-8-15

[10]
Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives.

Front Immunol. 2025-8-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索